ORIGIN 2017 DRCP R1 clean.pdf (378.98 kB)
Download file

Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial.

Download (378.98 kB)
journal contribution
posted on 26.01.2018, 17:53 by Tom Yates, Melanie J. Davies, Hyejung Jung, Jackie Bosch, Giatgen A. Spinas, Seamus Sreenan, Patrick Commerford, Hertzel C. Gerstein, ORGIN investigators
AIMS: To quantify whether insulin therapy, and concomitant weight gain, affects recreational physical activity and TV viewing time using data from the Outcomes Reduction with an Initial Glargine Intervention (ORIGIN) trial. METHODS: 12,537 insulin-naïve individuals with dysglycaemia were randomised to receive either basal insulin glargine or standard care and followed for a median of 6.2years. Complete recreational physical activity and TV viewing time questionnaires across baseline, 2year follow-up and study end were available for 8954 participants. Differences between groups at follow-up were assessed by analysis of covariance. RESULTS: At follow-up, there was no difference in physical activity or TV viewing time between those taking insulin glargine and those receiving standard care, despite body weight increasing by 1.66 (7.56) kg in the insulin glargine group and reducing by -0.65 (7.90) kg in the standard care group (P<0.001). The dose of insulin glargine was not associated with changes in physical activity. CONCLUSIONS: Despite modest weight gain, insulin glargine did not adversely impact recreational physical activity levels within an international cohort with dysglyaemia. ORIGIN ClinicalTrials.gov number: NCT00069784.


The ORIGIN trial was funded by Sanofi. The funders had no role in the analysis or interpretation of the data presented in this manuscript.



Diabetes Research and Clinical Practice, 2017, 132, pp. 137-143

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Diabetes Research Centre


AM (Accepted Manuscript)

Published in

Diabetes Research and Clinical Practice


Elsevier for International Diabetes Federation





Acceptance date


Copyright date


Available date


Publisher version



The file associated with this record is under embargo until 12 months after publication, in accordance with the publisher's self-archiving policy. The full text may be available through the publisher links provided above.